Achieve Life Sciences Inc (ACHV)
Achieve Life Sciences, Inc. is a late-stage pharmaceutical company focused on developing and commercializing cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. Cytisinicline is a plant-based alkaloid designed to act on nicotine receptors in the brain and help reduce the severity of nicotine withdrawal symptoms. The company has licensing and supply agreements with Sopharma AD and the University of Bristol. Achieve Life Sciences is headquartered in Bothell, Washington, and its common stock trades on the NASDAQ under the symbol ACHV.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACHV
|
$6.12
|
-21.4% Downside
|
Overvalued
|
$13.83
|
77.8% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
763.5 M
|
591.2 M
|
1.9%
|
72.6%
|
-1.4
|
41.2%
|
